Adjuvant immunotherapy (BCG) in stage D prostate cancer

Am J Clin Oncol. 1982 Feb;5(1):65-8.

Abstract

Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p less than 0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / therapy*
  • Aged
  • BCG Vaccine / therapeutic use*
  • Castration
  • Estrogens / therapeutic use
  • Humans
  • Male
  • Prospective Studies
  • Prostatic Neoplasms / therapy*
  • Random Allocation

Substances

  • BCG Vaccine
  • Estrogens